Ratings Surmodics, Inc.

Equities

SRDX

US8688731004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
41.96 ^USD	-0.07%		-0.33%	+15.43%

May. 30	Barrington Research Downgrades SurModics to Market Perform From Outperform	MT
May. 29	Needham Downgrades SurModics to Hold From Buy	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

Low profitability weakens the company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SURMODICS, INC.	+15.43%	599M	C
ABBOTT LABORATORIES	-5.27%	180B	C+
MEDTRONIC PLC	-0.05%	108B	C
BECTON, DICKINSON AND COMPANY	-1.50%	68.29B	A
DEXCOM, INC.	-7.12%	46.96B	B-
CENCORA, INC.	+15.24%	45.64B	B-
HOYA CORPORATION	+7.77%	42.41B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+18.56%	31.01B	B
TERUMO CORPORATION	+16.55%	25.51B	A-
ZIMMER BIOMET HOLDINGS, INC.	-6.84%	23.17B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes